News

With bipartisan support, the National Plan to End Parkinson’s Act has been reintroduced in the U.S. House and Senate. The legislation aims to unite the federal government in a coordinated effort with the private sector to cure and prevent the neurodegenerative disease. Said to be the first legislation devoted…

The greater the loss of dopamine transporter (DAT) protein in a brain region significantly affected by Parkinson’s disease — the striatum — the more severe are patients’ motor and nonmotor symptoms over time, particularly for men, a study reported. DAT levels were assessed with DAT imaging, a scanning technique…

Dipraglurant, an investigational oral therapy from Addex Therapeutics, eased motor and nonmotor symptoms associated with Parkinson’s disease in rodent models, a study showed. Along with being rapidly absorbed in the bloodstream, dipraglurant demonstrated anti-parkinsonian effects and reduced behaviors associated with anxiety, depression, and obsessive-compulsive disorder in mice and…

AT-04 and AT-07, experimental therapies Attralus is developing to treat Parkinson’s disease and other neurodegenerative disorders, are able to potently bind to several proteins that form toxic clumps in these conditions. That’s according to new data shared at the AD/PD 2023-International Conference on Alzheimer’s and Parkinson’s Diseases and…

Older age at the onset of disease, high blood pressure, poor cognitive and motor function, and mutations in the APOE gene are risk factors of future cognitive impairment in newly diagnosed Parkinson’s disease, a study showed. The combination of these factors was able to more accurately predict which patients…

Parkinson’s Awareness Month in April is a global opportunity to bring attention to the progressive neurodegenerative disease, as well as to educate communities about available resources, according to patients and advocates. Since 1997, World Parkinson’s Day has been celebrated on April 11. It commemorates the birth of James Parkinson, the…

Parkinson’s disease patients carrying severe variants in the GBA gene, a known genetic risk factor, experience faster motor and cognitive decline than those without such mutations, a Chinese study shows. Faster motor function decline was primarily driven by worsening bradykinesia (slow movements) and axial impairment (walking, posture, and balance…

One year of treatment with Anavex 2-73 (blarcamesine) safely led to a reduction in symptom severity for 20 people with Parkinson’s disease dementia in an extension study of the Phase 2 ANAVEX 2-73-PDD-001 trial. This finding was in sharp contrast with the worsening of symptoms observed in the months that…

Wren Therapeutics has developed oral small molecules that suppress the production of toxic alpha-synuclein protein forms in cellular and mouse models used to study Parkinson’s disease. The potential first-in-class molecules were designed with Wren’s technology platform to hinder processes involved in the generation of alpha-synuclein oligomers, the…

Blocking the activity of the synuclein nitrase enzyme reduced the levels of toxic clumps of the alpha-synuclein protein and lessened paralysis in mouse models of Parkinson’s disease, according to new data from Nitrase Therapeutics. Formation of toxic aggregates of alpha-synuclein is a hallmark of Parkinson’s and “has been…